Exploring metastatic breast cancer immunotherapies: Are ADCs and ICIs the answer?

Breast cancer is the most common malignancy in women and the second most common cancer worldwide.1 Rates of breast cancer are increasing in many parts of the world, reflecting its association with social and lifestyle factors related to economic development, as well as increases in life expectancy.2

How patient-centricity embeds value and stability in LTFU studies

Phase I-III randomized controlled trials alone are not generating enough data to extrapolate conclusions and theories about therapeutics to the global population. Not all drugs demonstrate the same efficacy in the real world as shown in the clinical trials. Because of this, we are seeing a rise in long-term follow-up (LTFU) studies that follow patient responses to a given treatment over five, 10 or 15 years, depending on the treatment.

Biomarker Q&A: The power of precision medicine for kidney disease

Labcorp Drug Development has continued to invest in the technology, capacity and expertise globally to support the evolving and complex analytical needs of our clients. We recently spoke with Katherine T Landschulz, PhD, Sr. Director and Lead Scientist, Cardiovascular and Metabolic Disease, Neurodegeneration at Labcorp Drug Development, to learn about the power of emerging biomarkers and new opportunities for precision medicine approaches in kidney disease. 

Labcorp Named One of the World's Most Admired Companies™ by FORTUNE® Magazine

BURLINGTON, N.C. , Feb. 1, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's list of the World's Most Admired Companies™, a recognition of the most respected and reputable companies

What the latest changes to EU regulations and data requirements mean for your microbial biopesticide registrations and renewals

Despite perceptions that biopesticides are inherently less dangerous, the EU regulates them as stringently as conventional, potentially highly hazardous, synthetic plant protection chemicals (Regulation [EC] No. 1107/2009). This has made approvals costly and slow. Recent regulatory revisions intended to redress this—to give EU farmers better and faster access to biological alternatives—may paradoxically increase the regulatory burden. Read on to learn what this may mean for registration or renewal of your biopesticide.

Delivering solutions to the next generation of cardiovascular medicines

JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning

Improving access to rare disease trials by incorporating DCT elements

Welcome to the February 2023 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. With Rare Disease Day coming soon on February 28, we are going to focus on how patients, sites and investigators can benefit by improving the design and execution of rare disease trials.

A conversation on PrEP and its impact on new HIV cases

Faster access to biopesticide alternatives to conventional pesticides under the U.S. BPPD regulatory framework

There is pressure worldwide for better, faster access to biological alternatives to conventional crop protection chemicals (CPCs). The U.S. Environmental Protection Agency (EPA) is ahead of regions such as the European Union (EU) in revising its regulatory approaches for biopesticides and in having a division dedicated to them, namely, the Biopesticides and Pollution Prevention Division (BPPD). Read on to discover how this can help you speed your biopesticide to market in the U.S. 

Innovative collaboration between Biomakers and Labcorp to provide greater access to oncology patients in Latin America

In December 2022, Labcorp and Biomakers signed an agreement that will positively impact thousands of cancer patients in Latin America through greater access to diagnostic molecular profiling and participation in clinical trials.